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ABSTRACT
Over the past decade, testing the genes of patients and their specific cancer types has become standar-
dized practice in medical oncology since somatic mutations, changes in gene expression and epigenetic
modifications are all hallmarks of cancer. However, while cancer genetic assessment has been limited to
single biomarkers to guide the use of therapies, improvements in nucleic acid sequencing technologies
and implementation of different genome analysis tools have enabled clinicians to detect these genomic
alterations and identify functional and disease-associated genomic variants. Next-generation sequencing
(NGS) technologies have provided clues about therapeutic targets and genomic markers for novel clin-
ical applications when standard therapy has failed. While Sanger sequencing, an accurate and sensitive
approach, allows for the identification of potential novel variants, it is however limited by the single
amplicon being interrogated. Similarly, quantitative and qualitative profiling of gene expression changes
also represents a challenge for the cancer field. Both RT-PCR and microarrays are efficient approaches,
but are limited to the genes present on the array or being assayed. This leaves vast swaths of the tran-
scriptome, including non-coding RNAs and other features, unexplored. With the advent of the ability to
collect and analyze genomic sequence data in a timely fashion and at an ever-decreasing cost, many of
these limitations have been overcome and are being incorporated into cancer research and diagnostics
giving patients and clinicians new hope for targeted and personalized treatment. Below we highlight
the various applications of next-generation sequencing in precision cancer medicine.
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Applications of Next-generation sequencing
Identification of genomic variants that underlie susceptibility
and causation of disease is of great interest. Next-generation
sequencing (NGS), or massively parallel sequencing (MPS), is
the ‘catch-all’ term used to describe a number of different
modern sequencing technologies that allow sequencing of
DNA and RNA much more quickly and cheaply than previ-
ously used Sanger sequencing [1,2].
NGS allows for an efficient method to identify and char-
acterize both known and novel variants at any location in
the genome. Currently, approaches to do this can be as
broad as whole-genome (WGS), whole-exome (WES), whole
transcriptome (RNA-seq) and targeted sequencing of specific
regions of the genome [3]. Many factors have to be taken
into account in deciding which approaches could be the
most suitable: budget, sample quality and quantity, depth of
coverage needed, etc [4]. A comparison of these different
approaches is summarized in Table 1.
In most cases a reference genome is available and the
DNA derived from a specific individual is tested for known
mutations or scanned for variation in entire regions, exomes
or smaller target regions.
The most comprehensive approach to interrogate the gen-
ome is through whole genome sequencing (WGS). In an
unbiased way, the entire genome can be sequenced and ana-
lyzed for the presence of mutations (both somatic and germ-
line), copy number variants (CVNs), and other chromosomal
structural variants including translocations, transversions and
inversions. Furthermore, this analysis is not limited to just
the coding regions of the genome, but also the non-coding
portions. As interest in these regions of the genome gains,
and functional mutations have been identified, WGS enables
the interrogation of them. Despite these advantages, the abil-
ity to generate enough sequence coverage throughout the
whole genome in a cost-effective manner remains a chal-
lenge. The high heterogeneity of many tumor types will
result in many variants being present at low frequency and
their identification would require a high read depth that is
often not achieved with WGS due to the cost of generating
sequence. Furthermore, the often high tumor heterogeneity
caused by extracellular matrix and other non-cancerous cells
can dilute the signal of a driver or pathological mutation.
Last but not least, the large amount of data generated
becomes a bioinformatic challenge, as vast amounts of com-
putational resources are needed to process and store the data
[5].
In comparison to WGS, targeted sequencing (TS)
approaches offer a more affordable and specific method for
CONTACT Paolo Fortina paolo.fortina@jefferson.edu Cancer Genomics and Bioinformatics Laboratory, Sidney Kimmel Cancer Center, Bluemle Life Science
Building 1009, Thomas Jefferson University, Philadelphia, PA 19107, USA
! 2016 Medisinsk Fysiologisk Forenings Forlag (MFFF)
SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION, 2016
VOL. 76, NO. S245, S84–S91
http://dx.doi.org/10.1080/00365513.2016.1210331
identifying genomic variants. With targeted approaches, as
much as whole exome, only a select few genes or the entire
coding regions, respectively, are sequenced. While with these
approaches, the ability to interrogate the entire genome is
lost and much of the information will be missed, there are
certain advantages to them over WGS. First, as only a small
region of the genome is being sequenced, a much higher
read depth can be achieved for a fraction of the cost com-
pared to WGS. This increased coverage enables identification
of low frequency mutations that otherwise would be missed
with WGS. Second, a comprehensive approach will sequence
many regions of the genome that are not needed for disease
diagnostics or therapeutics. In fact, only a handful of genes
have repeatedly been associated with cancers. Therefore, tar-
geted cancer gene panels ranging from as little as a dozen to
several hundred genes where mutations are more likely to
occur in specific regions or hotspot, have been readily incor-
porated into a clinical setting for disease diagnostics [6,7].
NGS platforms and technologies
DNA sequencing methods generally work by stopping the
process of copying the template strand using dideoxynucleo-
tides, reversible terminators or natural nucleotides [2].
Strategies for massively and ultrafast sequencing include
sequencing-by-hybridization, nanopore sequencing and
sequencing-by-synthesis (SBS). Most commercially available
platforms use the SBS technology where the sequence of a
template is inferred by stepwise primer elongation. The pro-
cess involves immobilizing the sequencing templates and pri-
mers on a solid support followed by base primer extension
and termination. The color of the fluorophore carried by the
extended base is recognized and then the fluorescent tag and
the 3-OH blocking group are removed and the steps are
repeated. The whole process has been popularized as a
second-generation sequencing technology on the Illumina
platform. Several optical systems can be utilized to monitor
synthesis of the complementary strand. In most cases four
different fluorescently labeled nucleotides are involved, but
recently Illumina introduced a three fluorescently labeled
nucleotide system for the NextSeq sequencer. In this case a
2-channel system is required to detect the red (C) and green
(T) signal, while the incorporation of A is detected in both
channels as yellow and no signal is interpreted as G incorp-
oration [8].
Non-optical detection systems are available including
semiconductor-based sequencing commercialized by Fisher
Scientific (Waltham, MA). In the Ion Torrent, also an SBS-
based sequencer, reactions take place in a semiconductor
chip, which detects the hydrogen ions produced during DNA
polymerization. Following clonal amplification, the DNA
library fragment is poured sequentially with each nucleoside
triphosphate and incorporated into the new strand by com-
plementary to the nucleotide on the target strand. Each time
a nucleotide is successfully added, a hydrogen ion is released,
and is detected by the sequencer’s pH sensor. The Ion tor-
rent sequencing is the first commercial platform to use non-
fluorescence and camera scanning making it a cost-effective
tool compared to other methods. Its main disadvantage is
the difficulty to decode repetitive sequences, such as, for
example, a homopolymer repeat of length 6 which may gen-
erate a pH change indistinguishable from a homopolymer of
length 8 [9].
All SBS sequencing systems rely on DNA amplification
and therefore are unable to perform single-molecule sequenc-
ing. Helicos Biosciences previously reported a single-molecule
technique; however, its dependence on reversible terminators
limited it to the analysis of short DNA fragments [10].
Pacific Biosciences (Menlo Park, CA) solved the single-
molecule challenge by developing the zero-mode waveguide
(ZMW) array, a nanostructured device that reduces the
detection chamber volume to the zeptoliter (10!21L) range
representing an improvement of three orders of magnitude
over confocal fluorescence microscopy. At this resolution vol-
ume/resolution, an estimated single molecule in the detection
layer provides a very low signal-to-noise ratio. To perform
parallel sequencing, inside each ZMW, an active DNA poly-
merase with one molecule of single-stranded DNA template
is immobilized on the bottom surface through which light
can penetrate and create a visualization chamber that allows
monitoring in real-time monitoring of the activity of the
DNA polymerase activity as it traverses a single molecule. To
allow uninterrupted monitoring of nucleotide incorporation,
four discrete fluorescent dyes on a synthetic nucleotide’s ter-
minal phosphate group rather than on the base, are
employed in the sequencing reaction [11–13].
A non-SBS, non-optical technology, single molecule
sequencing referred to as nanopore sequencing works by
feeding a small molecule through a membrane-spanning pro-
tein channel in a buffered ion solution. When a voltage is
Table 1. Comparison of our Next Generation Sequencing approaches.
Whole Genome Sequencing (WGS) Whole Exome Sequencing (WES)
" Comprehensiveness
" Detection of all the variants present in a genome
" Detection of structural and CNVs
" Hypothesis-free and gene discovery
" Lowest depth of coverage
" Highest data complexity
" Required high quality
" Interrogates protein-coding regions
" Cost-effective
" Gene discovery
" Required high quality
" Hard to identify structural variations
" Increasing coverage depth over WGS
Transcriptome sequencing or RNA-seq Targeted Sequencing (TS)
" Detection of variants present in the
" trascriptome and fusion genesRNA editing
" Differential expression
" Hard to identify variants in low expression transcript
" Required high quality RNA
" Regions of interest
" Highest depth of coverage
" Hypothesis-driven
" More manageable data storage and analysis
" Optimized also for low quality DNA (e.g. FFPE)
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applied across the membrane, an ionic current is induced
through the protein nanopore. As a molecule passes through
the pore, one base at a time, it produces a measurable dis-
turbance in the ion current providing information to
decipher the sequence of the molecule. The technology is
scalable and has been commercialized on a device, the size of
a USB memory stick, the MinION, by Oxford nanopore
(Oxford, UK) to distinguish between nucleotide bases [14].
The Oxford Nanopore’s ‘strand sequencing’ advantages are
that it can read much longer strands of DNA than other
sequencing methods, requires unamplified DNA, removing
the need for PCR and less sample. In principle these features
make it possible for a doctor to read a patient’s DNA directly
from a blood sample [15]. A summary of widely used NGS
sequencers and their technologies is shown in Table 2.
There are four core steps in the standard workflow associ-
ated with NGS: (1) sample preparation; (2) amplification; (3)
sequencing; and (4) data analysis. In most cases, after nucleic
acid extraction, DNA is fragmented to generate smaller
strands by physical methods like acoustic shearing or by
enzymatic methods. Based on the NGS-platform, the strands
are ligated to double-stranded pieces of synthetic DNA
referred to as adapters, enabling the sequence to become
bound to a complementary counterpart for library construc-
tion by clonal bridge amplification or emulsion PCR.
Platform-specific adapters allow multiplex samples to be clo-
nally amplified being spatially arranged or separated.
Numerous kits for making sequencing libraries from DNA
and RNA are available commercially from a variety of ven-
dors. Library size is determined by the desired insert size
while optimal insert size is determined by the limitations of
the NGS instrumentation and by the specific sequencing
application such as WGS, WES, coding and non-coding
RNA sequencing and target gene resequencing. Finally, a bio-
informatics pipeline is required to process and analyze all the
collected information and to detect the genetic variant by
sequence alignment, quality assessment, variant calling and
variant association.
For targeted genomic assays, several methods are available
for capture and sequencing of specific genes and regions rele-
vant to the tumor type. They can be subdivided in two main
classes: (1) enrichment by amplification; and (2) enrichment
by hybridization [16]. The former involves several locus-spe-
cific primer pairs and a multiplexed amplification reaction.
Small amounts of DNA are required to achieve deep cover-
age of specific regions of interest. This type of panel typically
interrogates discontinuous regions around hotspot mutations
and not the entire coding sequence of the gene of interest.
Therefore, this method is most suitable in testing FFPE sam-
ples and is not recommended for detection of structural
alterations (CNVs and translocations). Enrichment by
hybridization or hybridization capture requires more input
and higher quality DNA. Therefore, it is most suitable for
fresh or frozen samples where synthetic DNA or RNA
probes, specific to the genomic area of interest, bind the
complementary sequence on the genomic DNA, followed by
target capture and amplification. This method can detect
copy number gain and loss and selected structural rearrange-
ments [16]. Several probe-captured based technologies are
available (TruSeq and Nextera, Illumina, San Diego, CA;
Sureselect and Haloplex, Agilent technologies, Santa Clara,
CA). These methods are performed on a bench-top or pro-
duction sequencer like Illumina or Ion Torrent.
Several studies have already tested and compared different
enrichment technologies, and could be used as a guide in the
selection of the most appropriate procedure. Comparisons
have been made between a few technologies and data were
analyzed using a variety of parameters including the percent-
age of targeted bases covered by probes and by sequence
reads, e.g. design coverage and sensitivity, respectively, and
the number of reads mapping to the targeted sequence, e.g.
specificity. Uniformity and reproducibility or overall vari-
ation in per-base coverage over the targeted region and
Table 2. A summary of widely used next-generation sequencers and their technologies.
Company Sequencer
Library
amplification Carrier
Sequencing
technology Detection method Comments
Illumina Inc MiniSeq
MiSeq
Hiseq
NextSeq
Bridge PCR Flow cell Reversible termin-
ator SBS
Optical detection of
fluorescence from
dye-labeled
nucleotides
75–600 bp
Capability: WES, WGS, tar-
get seq, WTS
Life Technologies Ion PGM
Ion Proton
emPCR Ion Chip Semiconductor-
based SBS
Transistor-based detec-
tion of Hþ shift
after nucleotide
incorporation
200 and 400 bp
Capability: WES, WTS, tar-
get seq
Qiagen GeneReader NA Flowcell SBS Fluorescence detection 12 gene cancer test:
Actionable Insight Tumor
Panel
Pacific Biosciences RS II
Sequel
NA SMRT cell Single Molecule
Real Time
sequencing
Real-time fluorescence
detection
up to 40,000 bp
Capability: WES, WGS, WTS,
target seq, de novo gen-
ome assembly
Oxford Nanopore MinION
PromethION
GridION
NA Protein
nanopore
ssDNA nanopore-
based
Change in electrical
Field
Up to 10,000 bp
Capability: WES, WGS, WTS,
target seq, de novo gen-
ome assembly
Complete Genomics – BGI Revelocity
Sequencing
System
Combinatorial
Probe-Anchor
Ligation (cPAL)
DNA nano-ball
(DNB array)
Ligation-based
cPAL
sequencing
fluorescence detection Restricted to WGS WES
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variation between replicates, respectively, were also taken
into account [17,18].
Cancer panel-gene targeted sequencing: challenges
and outcomes
The use of NGS in cancer screening has generated a large
catalog of potential somatic tumor mutations that cover dif-
ferent exons in a large number of genes, available for both
solid and liquid tumors. An ‘actionable’ genomic mutation is
defined when ‘it is potentially targetable with a US Food and
Drug Administration (FDA)-approved drug or other agent
that can be used in early clinical trials’ [19]. Serial single-
gene testing could be time consuming especially for FFPE
tumor biopsies; therefore, hot-spot based assays or cancer
panels covering actionable variations that could affect
patient’s treatment choice are widely used to identify single
validated variants [20,21]. Therefore, through a comprehen-
sive genomic analysis, patients may benefit from genotype-
directed therapy or genotype-matched clinical trials.
The decision about how and which genes to sequence
requires consideration of the number of cases, cost, accessi-
bility to matched normal tissue and turn-around-time. One
option is to outsource the entire process to a commercial ref-
erence laboratory. A wide variety of commercially pre-
designed panels are available and are listed in Table 3 with
the reference laboratory performing cancer targeted rese-
quencing [4,16]. Most also can be customized with the add-
ition of relevant genetic variants and non-coding sequence
information such as promoters and/or regulatory regions.
Furthermore, to provide more flexibility and allow screening
of specific genes relevant only to a specific tumor type, most
companies have made either large or small cancer-specific
panels where the customer can select not only genes, but
also which area of those genes have to be analyzed. However,
setting up an in-house panel allows the laboratory the flexi-
bility of adding new biomarkers and variants as soon as new
evidence or clinical trials are available. In addition, the
laboratory has access to all data (quality, frequencies, etc.),
custom pipelines for bioinformatic analysis and results may
be integrated with associated clinical information. Finally,
once the assay is validated it can be used on other samples
or optimized for other types of specimens.
Tumor heterogeneity
An emerging field of interest is the analysis of tumor hetero-
geneity, cell clonality and effects on therapy response. The
possibility of easily accessing sample tumor cells over time
allowed for the identification of a wide range of driver muta-
tions in many NGS studies and also facilitated the investiga-
tion of tumor frequency over time [22]. Analysis of cancer
genomes of solid tumors presents several challenges. Tumor
biopsies are often arduous to obtain because of quantity and
quality. They usually contain a mixture of tumor cells and
non-tumor cells, and some of the tumors are highly hetero-
geneous [23]. Therefore, to achieve desirable detection sensi-
tivity, a high coverage of sequencing may be required
(500–1000X). To address this, custom-targeted NGS panels
have been developed, especially for large numbers of samples
where the optimal choice is to genotype the primary tumor,
matched non-tumor tissue, and, if available, recurrent meta-
static sites. One example is the MSK-IMPACT, a hybridiza-
tion capture-based, next-generation sequencing assay for
interrogating somatic alterations in 341 oncogenes and tumor
suppressors in formalin-fixed, paraffin-embedded (FFPE)
tumor specimens [24]. Patient-matched tumor and normal
samples were sequenced and then sensitivity, specificity, and
reproducibility of the MSK-IMPACT panel assessed through
the validations on 284 known positive tumor samples with
predefined point mutations and insertions/deletions variant
detected at 500$ coverage depth. Detection limit for low fre-
quency variants in hotspot mutation and non-hotspot muta-
tion was 2% and 5%, respectively [24].
The main concerns about clinical genomics and the
sequencing data generated is how they currently impact ther-
apy decisions, whether they can lower the costs of health
care, improve survival rate and/or improve quality of life.
The number of publications reporting clinical utility of com-
prehensive genomic profiling in cancer patients is still
Table 3. Commercially available pre-designed panels and representative reference laboratories performing cancer-targeted
resequencing.
Vendor Assay name No. of genes
Illumina, Inc (San Diego, CA) TruSight Cancer 94
TruSight Tumor 15 15
TruSight Myeloid 54
TruSeq Amplicon Cancer Panel 48
Thermo Fisher Scientific (Waltham, MA) Ion AmpliSeq Cancer Hotspot Panel v2 50
Ion Ampliseq Comprehensive Cancer Panel 400
Qiagen (Hilden, Germany) Actionable Inside Tumor Panel 12
Agilent Technologies (Wilmington, DE) ClearSeq Comprehensive 151
ClearSeq Cancer 47
ClearSeq AML 20
Cancer Research Panel 47
Foundation MedicineVR , Inc (Cambridge, MA) Foundation One 315
University of Washington (Seattle, WA) UW-Oncoplex 234
ParadigmDX (Phoenix, AZ) PCDx 114
ARUP Lab (Salt Lake City, UT) Solid Tumor Mutation Pannel 48
Caris Life Science (Irving, TX) MI Profiles 46
Knight Diagnostic Lab (Portland, OR) GeneTrails Cancer Gene Panel 38
PathGroup (Brentwood, TN) SmartGenomics 35
Life Technologies (Carlsbad, CA) Pervenio Lung NGS assay 25
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limited. In June 2015 the American Association Cancer
Research Precision Medicine Series conference took place to
discuss the integration of NGS into clinical practice. One
study highlighted potential benefits using precision medicine
approaches [25]. A 100 gene-targeted panel was evaluated for
identification of molecular targets in metastatic patients of
diverse cancer types. The cohort of 72 cancer patients was
subdivided into two groups; 36 patients received standard
care and the other 36 were treated using a precision medi-
cine approach. Progression-free survival (PFS) and total
treatment costs were taken into account to establish if the
precision medicine approach would improve PSF of the
metastatic cancer patients without increasing healthcare
costs. The precision medicine group showed an increase in
PSF with comparable total costs [26]. In a second study, a 48
NGS gene panel was employed to analyze 1893 cancer
patients with different histologies in a retrospective study.
Although 13% could not be analyzed due to low DNA qual-
ity or lack of sufficient FFPE material, 80% of all other tested
samples showed at least one mutation. Unfortunately, only
5% of these patients followed a genotype-matched clinical
trial, and did show a better response, emphasizing the need
to improve on design of these kinds of trials [27].
Tumor heterogeneity, drug resistance and liquid
biopsy
The intra-tumoral heterogeneity and clonal evolution under
treatment selection pressure are two causes for tumor recur-
rences. Cancer cells in a slowly-proliferating or even ‘dor-
mant status’ may continue to accumulate genetic and
epigenetic alterations that may conceal metastases.
Acquisition of resistance to therapy could be due to tumor
heterogeneity or influenced by an appropriate reaction to
treatment regimen.
NGS studies should be designed to detect heterogeneity
and the dynamic status of the tumor. Unfortunately, solid
biopsies do not fit this need, due to sample collection chal-
lenges including accessibility, especially during the course of
the disease. Most often the procedure for sampling is inva-
sive and even if available, the region obtained may not be
representative of overall tumor heterogeneity.
Circulating tumor cells (CTCs) and circulating cell-
free tumor DNA (cfDNA)
Circulating tumor cells (CTCs) and circulating cell-free
tumor DNA (cfDNA) can be a source of cancer material,
representative of disease status and compatible with repeti-
tive, non-invasive sampling [28,29]. Use of cfDNA and CTCs
enable testing patients over time and may overcome the need
for serial solid biopsies.
The cfDNA are released into the bloodstream from tumor
tissue and from lysis of CTCs. For this reason cfDNA and
CTCs must be considered as two separate entities [30].
Several challenges are associated with cfDNA analysis since it
represents fragmented DNA (160–180 bp) [31], is usually
present at low concentrations and can be mixed with non-
tumor DNA. The pre-analytical steps can have significant
impact on analysis and the final yield. In addition, high sen-
sitivities are often required to detect variation expected at a
frequency of <0.1%. One of the best methods to achieve this
level of sensitivity is the digital PCR (dPCR) droplet system,
especially when a limited number of loci need to be eval-
uated [32]. However, characterization of rare variants is often
a daunting task to track down by NGS because rare variants
may be difficult to distinguish from sequencing errors.
Template tagging methods such as Safe-Sequencing System,
or Safe-SeqS [33] and tagged-amplicon deep sequencing, or
TAm-Seq [34], have been developed to distinguish errors
from real variants to allow comprehensive cancer genomic
profiles [34]. The most immediate clinical application is in
identification of genomic alterations to guide selection of tar-
get therapies and to monitor in real time during disease pro-
gression and therapy.
CTCs are, like the cfDNA, extensively studied for their
potential clinical utility. They represent a rare population of
cells in the background of 106–107 nucleated blood cells and
they require a critical enrichment step before their detection
and characterization. Although they were first described by
T. R. Ashworth in 1869 [35] technologies have only recently
been developed to address enrichment challenges in terms of
capture efficiency/recovery rate, blood sample capacity, cell
viability and purity. The main strategy to enrich CTCs can
be based on biological features (like cell surface marker
expression) or on physical properties (like size, density or
deformability). The only currently FDA-approved technology
is CellSearchVR (Veridex, Rarithan, NJ), an EpCam-based cap-
ture method followed by immuno-fluorescent staining using
epithelial markers such as cytokeratin 8, 18, 19 and leuco-
cyte-specific marker CD45. However, this technology cannot
detect CTCs that may have undergone an epithelial to mes-
enchymal transition (EMT). This relevant subpopulation
may exhibit molecular and functional stem-like features
often correlated to chemo-resistance. The value of CTC
detection using the CellSearchVR was demonstrated in meta-
static breast, prostate and colon cancer patients [27,36,37].
In addition to the effort to characterize and detect CTCs,
recently several studies have demonstrated mutational pro-
files of CTCs in various cancer types. In one study, CTC-
enriched fractions using CellSearchVR from six metastatic
colorectal cancer patients were analyzed on a 68 cancer
panel NGS array, and all mutations found were confirmed
as subclonal mutations in primary tumors and/or metastases
[38]. Moreover, several new techniques to isolate and ana-
lyze single cells are allowing single CTC mutational analysis
to better investigate and understand the correlation between
tumor heterogeneity and drug resistance. DEParrayTM was
used to isolate single CTCs from the CellSearch CTCs-
enriched fraction, followed by single whole genome/tran-
scriptome amplification [39] and targeted or comprehensive
NGS analysis [40]. CTC-enriched cells from the CellSearch
system and cfDNA were investigated in 48 patients with
ERþ positive metastatic breast cancer receiving systemic
therapy [41]. This investigation involved 23 target genes
with hot spot mutations in the following genes: ESR1,
PIK3CA, TP53, FGFR1 and FGFR2. NGS detected three
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activating mutations in ESR1, three hotspot mutations in
PIK3CA and three in TP53 in baseline cfDNA. Only the
ESR1 p.D538G mutation was found in one matched circulat-
ing tumor cell sample. This can be explained by the fact
that only CTC pools were analyzed in which the predomin-
ant component is wild type, while the mutation was detected
in cfDNA at only 1% [41]. In another study, a single CTC
study on ERS1-activating mutations and their correlation
with endocrine therapy resistance showed feasibility and
potential clinical utility. ESR1 mutational status has been
successfully performed on 72 single cells isolated from meta-
static breast cancer patients, and mutations were reported in
patients with an acquired endocrine-based therapy resistance
[42]. The development of single-cell sequencing is making
CTCs a potential target to assess prognosis, monitor
response therapy and for rational selection of the best ther-
apy. All these studies suggest that blood-based biomarkers
can reveal uniquely the dynamics of primary tumor forma-
tion or metastases. CTCs and ct-DNA each can contribute
differently to detection of somatic variation at a frequency
of 1% or lower, which in most cases is impossible to differ-
entiate from noise using a solid biopsy specimen.
Clinical validation and ethical implications
The integration of these NGS technologies in any clinical
sequencing workflow requires analytic and clinical validation,
stringent regulations and guidelines established by the agen-
cies governing clinical laboratories. Clinical laboratories are
subject to legal obligations designed to ensure that tests meet
parameters for trueness, precision, sensitivity and specificity.
Organizations like the College of American Pathologists
(CAP) and the Association for Molecular Pathology (AMP)
have defined assay parameters for low-throughput assays and
have defined assay parameters (Table 4) for NGS sequencing
implementation in diagnostic settings [43,44].
One strategy to validate cancer NGS assays is to test sev-
eral tumor specimens with known somatic variants (inser-
tion-deletion, CNVs, SNVs, etc.) and detect that aberration
using another possible sequencing platform. Human cell lines
positive for somatic mutation or germ-line polymorphisms
with already characterized changes also can be used [8]. The
reference sample utilized for validation should mimic fea-
tures of the clinical samples for which the NGS assay is
being validated. The quality and quantity of the starting
material should be comparable to the clinical sample used.
Most cancer specimens are usually FFPE samples in which
nucleic acids are compromised, especially in quality.
Therefore, protocols must be optimized to deliver deep-
sequencing coverage for these kinds of specimens. Several
synthetic standards are available and can be used for NGS
validation. Theoretically, a synthetic standard or cell lines
can be used for each gene and variant, especially for which
one has a low allele frequency [8]. Cross-validation on differ-
ent NGS platforms is also suggested for a new NGS clinical
assay [8,45].
Matched germ-line DNA is typically used as a normal
control to distinguish inherited variants and to increase ana-
lytical sensitivity. There are ethical, social and legal implica-
tions in this kind of approach. The analysis can incidentally
reveal germ-line susceptibility to cancer or other diseases
(incidental findings) with significant consequences for the
patient and family members. Therefore, ethical considera-
tions are critical and genetic counseling should be available
to properly educate the patients as well as relatives if
required, about risk and benefit of each genetic test and
informed consent should be signed. Guidelines about how to
manage incidental findings in the clinical setting have been
released by the American College of Medical Genetics and
Genomics (ACMG) and the American Society of Clinical
Oncology (ASCO) [8,46,47].
Conclusions
Since January 2015 the ‘Precision Medicine’ initiative has
represented an attempt at disease prevention and treatment
that utilizes an individual’s variation in genes in order to
select the most appropriate therapeutic strategy for each
patient on the basis of individual variability. These
approaches offer much promise, but much work is still
needed to ensure sensitivity, specificity, timeliness, cost-
effectiveness and validity of such testing [48]. Furthermore,
clear actionable clinical treatment strategies must be defined
so that rationale for a precision medicine approach is clear.
Disclosure statement
The authors report no conflict of interest. The authors alone are respon-
sible for the content and writing of the paper.
Funding
This work was supported in part by the Kimmel Cancer Center
(Philadelphia, PA to PF). CP is supported by a Celsee Diagnostics
Research Grant.
Table 4. NGS assay parameters recommended to validate molecular diagnostic test.
Depth of coverage The minimum sequencing coverage of target region under standard assay conditions, for each type of variant, should be estab-
lished in order to achieve the required level of mutation detection.
Limit of detection The lower limit of mutation detection under standard assay conditions for different variants (SNVs, CNVs, insertion, deletion, etc.).
Accuracy The degree of concordance between NGS’s sequences obtained with the assay and the reference sequence.
Precision The degree of result reproducibility by the assay across users and runs.
Specificity The probability of the assay to not detect sequence variants where none are present among samples validation set
(false-positive rate).
Sensitivity Capability of the assay to detect true sequence variants among sample validation set (false-negative rate).
Reproducibility The capability of the assay to give consistent results within-run.
Reportable range Range of values over which the test is evaluated valid.
Reference range When a test has specific reference for designed population or study group.
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